Physician profile
Solly E Elmann
NPI 1447545421
$1,198.28
in general payments reported to CMS, 2019-2025
11 companies · $324 in 2025
The $324 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2020: $137 · 2021: $35.34 · 2022: $162 · 2023: $146 · 2024: $236 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $707.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $391.93 | 2021-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $324.13 | 2022-2025 | Clareon, Clareon Panoptix Pro |
| Aerie Pharmaceuticals, INC. | $125.00 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $117.48 | 2020 | |
| Abbvie INC. | $93.28 | 2022-2025 | |
| Oyster Point Pharma, INC. | $35.86 | 2022 | |
| Allergan, INC. | $32.25 | 2019 | |
| Amgen INC. | $22.17 | 2025 | Tepezza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Genentech USA, INC. | $19.04 | 2022 | |
| Optos, INC. | $17.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Solly Elmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.